Diabetes and Metabolic Disorders: The Approval of Teplizumab
Teplizumab, the first disease-modifying therapy for Type 1 diabetes, delays disease onset by ~4 years in high-risk individuals. Priced at $194,000 per course, it redefines early intervention despite cost barriers.
June 23, 2025
by David Orchard-Webb
Charting Pharma’s Future: How Mergers and Acquisitions Are Reshaping the Industry Landscape
In Q3 2024 (GlobalData’s Deals Database), the pharmaceutical sector saw 420 M&A deals valued at $32.4 billion, underscoring the ongoing importance of these transactions in shaping the future of the industry.
December 17, 2024
by Neeta Ratanghayra
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
The Dynamic Diabetes and Metabolic Disorder Treatment Landscape
Diabetes is a chronic medical condition characterized by high levels of glucose in the blood.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
Analysis on the Construction of Sustainable Development Capacity of Pharmaceutical Enterprises from the Aspect of Investment of R&D Expenses
Recently, semi-annual reports of domestic and foreign pharmaceutical companies have been disclosed one after another. From the data released by major companies, we put aside the highly anticipated...
December 17, 2021
by Zhulikou431
Discovering Biotechnology: Top 9 Chinese Pharmaceutical Companies in 2020
China 's pharmaceutical industry garnered a total revenue of about 2.6 trillion yuan in 2019 amounting to an eight percent year-on-year growth.
November 4, 2020
by Deborah Seah
Pharma Sources Insight October 2020 Focuses on Pharma Landscape in China
With over 4000 pharmaceutical companies, China is the second-largest pharmaceutical industry globally.
November 2, 2020
by Pharma Sources Insight
New computational method reduces risk of drug formulation
One major factor that determines the efficacy of a drug is the structure that its molecules form in a solid state.
February 2, 2019
by worldpharmanews
Global Medicine spending to exceeds $1.5 Tn by 2023
Opioid prescriptions per capita in the US are estimated to decline by one-half to one-third compared to current levels by 2023.
February 1, 2019
by biospectrumasia
Deloitte finds Pharma returns on R&D reach new low
Deloitte has found a sharp decline in the returns on investment from top pharmaceutical companies, with returns at almost half of what they were in 2010
January 4, 2019
by europeanpharmaceuticalreview
Innovent buys Chinese rights to Incyte drugs for $40M upfront
Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in development at Incyte.
December 18, 2018
by fiercebiotech
Most pharma firms doing little R&D for poorer patients
A ranking of pharma companies developing new medicines for low- and middle-income countries has revealed that just five companies are responsible for almost two-thirds of projects.
November 22, 2018
by pharmaphorum